Lun - Ven 8:00 - 17:00
These changes may be due to the vasodilator effect of sildenafil on female genital tissues.
Sildenafil was shown to be able to inhibit cGMP hydrolysis by high-affinity selective PDE5 inhibition in intact cells and in soluble extracts of human clitoral corpus cavernosum smooth muscle cells.
| Country | Legal Status | Prescription Required | Notes |
|---|---|---|---|
| USA | Approved for certain uses | Yes | Off-label for women often not approved |
| UK | Prescription-only | Yes | Approved for male ED; off-label use in women |
| Canada | Restricted use | Yes | Prescription required; variable by province |
| Australia | Prescription-only | Yes | Limited clinical guidelines for women |
Moreover, the finding of NO in human clitoral tissue (32) and vaginal tissue (33) could sustain the activity of sildenafil on female peripheral genital targets.
Arterial clitoral color Doppler ultrasound was performed at baseline and during the usage of drugs. All adverse events reported by the woman were recorded, irrespective of any random relationship with the study drug. Intention-to-treat analyses were performed for all efficacy variables and included all patients who had a baseline evaluation and had at least one efficacy assessment after the baseline visit. We included in the analysis the subjects that had missing information on one or more questionnaire items. The last observation carried forward was used to select data such that missing data were replaced by values from the last available assessment during treatment before the respective assessment.
Furthermore, women who stopped treatment for adverse events were included in the analysis. For comparisons among baseline, sildenafil 100 mg, and placebo sexual PEQ scores, the nonparametric Wilcoxon’s rank-sum test was used. Separate analyses were performed for the arousal score (primary end point) and desire, orgasm, enjoyment of sexual activities, satisfaction with frequency, and frequency of intercourse. Paired Student’s t-test was performed to compare changes between baseline sildenafil and placebo values of clitoral arterial blood flow. Considering the order in which the treatments were allocated, data was analyzed by Student’s t-test, using the Bonferroni method of correction for multiple comparisons if a significant F ratio was found.
Statistical analysis was carried out using the Primer of Biostatistics statistical computer package (29). Of the 36 women enrolled in the study, 32 women aged 27–41 with a mean age (±SD) of 33 (±3.1) and a BMI 25.0 ± 3.5 provided information at each treatment to be included in the analyses. Four women were excluded after assessment at baseline: [1] two for anovulatory cycles and [2] two for refused treatment. The mean duration of diabetes was 12.1 ± 8.5 years, and the mean HbA1c value was 8.0% ± 1.8%. Plasma concentrations of T (0.4 ± 0.6 ng/mL; normal range, 0.3–1.2 ng/mL), FT (1.3 ± 0.7 pg/mL; normal range, 0.3–3.2 pg/mL)19, and PRL (10.5 ± 3.5 ng/mL; normal range, 5–25 ng/mL) were normal. Some interesting clinical data showed sildenafil to be effective on both premenopausal (22) and postmenopausal (23) women affected by SAD, and data on asymptomatic premenopausal women using sildenafil to study the effects of the PDE5 inhibitor on the genital pathway showed increased sexual activity, mainly in genital arousal (34).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Oral Jelly | 100mg | 30 + 5 Sachets | 136.20€ 129.71€ | |
| Kamagra Oral Jelly | 100mg | 90 + 8 Sachets | 303.56€ 289.10€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Kamagra | 100mg | 360 + 6 Pills | 839.95€ 799.95€ | |
| Kamagra Soft Tabs | 100mg | 60 + 4 Pills | 180.59€ 171.99€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Kamagra Oral Jelly | 100mg | 220 + 18 Sachets | 662.24€ 630.70€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra Polo | 100mg | 84 + 4 Pills | 244.49€ 232.85€ | |
| Viagra Generic | 25mg | 10 Pills | 25.19€ 23.99€ | |
| Viagra Generic | 50mg | 90 + 6 Pills | 107.37€ 102.26€ | |
| Viagra Generic | 150mg | 60 + 4 Pills | 111.25€ 105.95€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ |
Ours was the first study on the effects of sildenafil on clitoral blood flow in diabetic women using color Doppler ultrasound.
Moreover, 4 (12.5%) of 32 women in the B sequence did not complete the study for adverse events, all during sildenafil usage. They sildenafil 100 mg cost stopped taking the drug for [1] headache, vision problems, and nausea (n = 1), [2] vision problem and headache (n = 1), and [3] headache and nausea (n = 2). Therefore, the incidences of the most commonly recorded adverse events reported by subjects during the use of sildenafil were headache (12.5%), nausea (6.2%), and vision problem (6.2%). Each adverse event was predominantly transient and mild in nature. During the study, each women had well-controlled diabetes.
The mean HbA1c value obtained during each treatment was similar to that observed at baseline (P=NS). The BMI did not show any significant variation with respect to baseline values (P=NS). The sexual interview showed that the mean duration of sexual dysfunction was 3.5 years (range, 2.2–4.5 years). Subjects mainly reported arousal and orgasm difficulties and dyspareunia. Moreover, they reported a decrease in sexual satisfaction and in sexual activity.
The mean (±SD) usage of sildenafil and placebo was, respectively, 2.1 (±0.4) and 2.9 (±0.4) times weekly. It is interesting to note that all women recorded using each drug for all sexual activities. Changes in sexuality produced by drug administrations were noticed though the analysis of PEQ items. Table 1 shows the changes from baseline of qualitative and quantitative sexual behaviors according to the treatment and the efficacy of sildenafil and placebo. Data indicate that sildenafil improved [1] the experience of arousal (P<.001), orgasm (P<.001), and enjoyment (P<.001) with respect to baseline; and [2] the experience of arousal (P<.01) and orgasm (P<.05) with respect to placebo. An interesting study was conducted with healthy postmenopausal women to examine the effects of sildenafil on both clitoral and uterine blood flow by color Doppler ultrasound (35). After sildenafil administration each mean index showed improvement in blood flow, even if the Doppler measurements of the clitoris and uterus were not equal, probably due to the dense concentration of PDE5, which is highly expressed in clitoris erectile tissue in comparison to other female genital tissues (36, 37).
Excluding the frequency of intercourse (P<.05), each aspect of sexuality during placebo intake was similar to that observed at baseline (P=NS). During sildenafil intake, dyspareunia decreased with respect to baseline and placebo (P<.05). Finally, desire and frequency of fantasies did not change during both treatments with respect to baseline (P=NS). All women enrolled in the study underwent baseline color Doppler ultrasound; at the end of the A sequence, 32 women (response rate, 88.9%) underwent color Doppler ultrasound, while at the end of the B sequence 28 women (response rate, 77.7%) underwent color Doppler ultrasound. Table 2 shows the results of the color Doppler ultrasound measurements and statistical analysis.
In both the A and B sequences of drug administration, sildenafil improved clitoral blood flow with respect to placebo (P<.05). During sildenafil administration, the mean PSV (16.78 ± 1.65) markedly increased and the mean EDV (−5.1 ± 1.2) significantly decreased from baseline. On the contrary, placebo was not able to produce any change with respect to baseline (P=NS). Moreover, the mean RI (0.71 ± 0.32) was significantly lower and the mean PI (1.81 ± 0.77) was significantly higher compared with both baseline and placebo values (P<.05). Our study was the first to take into consideration type 1 diabetic women treated with sildenafil.
In our pilot study, the treatment with 100 mg sildenafil was effective in modifying both sexuality and clitoral blood flow in premenopausal women with type 1 diabetes. Techniques measuring hemodynamic changes in the vagina and clitoris using clitoral tissue concentrations of hemoglobin, vaginal luminar pressure, and clitoral intracavernosal pressure could involve noninvasive instruments (8). However, we should use more direct diagnostic procedures to evaluate hemodynamic events of vaginal and clitoral pathways. The color Doppler ultrasound has become a first-level diagnostic procedure to measure the penile blood flow of men with ED (30) and might be a useful method to study the female sexual response by measuring clitoral blood flow (31). By color Doppler ultrasound, we observed a decreased mean RI and an increased mean PSV and PI of the clitoral artery. Besides studying the effect of diabetes on arousal, orgasm, and desire and its role in provoking sexual pain, we took into consideration the change of sexual enjoyment and both satisfaction with and frequency of sexual activity.
The efficacy of treatment was the primary end point based on the proportion of successful attempts, defined as sexual arousal levels, occurring after dosing. Safety was considered a further end point of this study, data being collected throughout the study period, and included recording adverse events, vital signs, and changes in laboratory test values for standard hematology and biochemistry variables. Patients provided information recorded on diary cards and were reviewed at each study visit concerning sexual activity. After defining inclusion criteria at the screening, according to a computer-generated list of random number groups, each woman was randomly allocated to one of the two possible sequences, each of which constituted two medication series: sildenafil 100 mg/placebo (A sequence) and placebo/sildenafil 100 mg (B sequence). Women were assessed before being treated and during each treatment by one investigator.
Both the woman and the attending doctor carrying out the procedure were blinded to the two drugs. The investigator was not involved in the recruitment of the women and did not know the computer-generated randomization list and the assignment of the treatment group according to the sequence of recruitment. The codes were broken after the study was completed. The crossover study design was used to define whether the treatment with sildenafil was effective with respect to placebo. Each woman took sildenafil or placebo 1 hour before each sexual intercourse.
The usage of the drug was not more than once daily. Each woman received each treatment for 8-week periods. There was a 7-day washout period between treatments. We chose a 1-week washout period on the basis of our previous studies using a similar intervention by which we did not observe any carryover effect (22, 34). The PEQ was used at baseline, at the washout, and after treatments. In contrast to previously reported data, in our study women with type 1 diabetes did not suffer from sexual desire dysfunction (6, 38, 39), which was investigated by both the SHI and the PEQ.
Because diabetes produces vascular pathologies and microangiopathy, vasoactive drugs could be used to treat genital arousal dysfunction in diabetic women.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités